Hege Frøen

Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.

P. Sandset, A. Ree, W. Ghanima, 2020, Thrombosis research.

Cold agglutinin disease revisited: A multinational, observational study of 232 patients.

T. Tvedt, A. Małecka, S. Berentsen, 2020, Blood.

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow‐up

P. Sandset, A. Ree, W. Ghanima, 2022, Journal of thrombosis and haemostasis : JTH.

“Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients ‐ 30 months follow‐up”: Reply

P. Sandset, A. Ree, W. Ghanima, 2022, Journal of thrombosis and haemostasis : JTH.

Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up

P. Sandset, A. Ree, W. Ghanima, 2021, Blood.

Arterial events in cancer patients treated with apixaban for venous thrombosis.

P. Sandset, A. Ree, W. Ghanima, 2023, Thrombosis research.